Year All2024202320222021 11/12/2024 Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Read More 11/6/2024 Neumora Therapeutics to Participate in Upcoming Conferences in November Read More 10/29/2024 Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 Read More 8/14/2024 Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders Read More 8/6/2024 Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Read More 6/20/2024 Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation Read More 5/14/2024 Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression Read More 5/7/2024 Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Read More 5/6/2024 Neumora Therapeutics to Participate in Upcoming Conferences in May Read More 4/15/2024 Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study Read More
11/12/2024 Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Read More
10/29/2024 Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 Read More
8/14/2024 Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders Read More
8/6/2024 Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Read More
6/20/2024 Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation Read More
5/14/2024 Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression Read More
5/7/2024 Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Read More
